Insulet Corp.
PODDLast close · Oct 16, 2026141.10+2.33 (+1.68%)
Market cap$9.8B
11 firms' latest targets, last 90 days: median $174.00 ($144.00–$190.00), 23% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-12 | Jefferies | $190.00 | ▼ 52% | +35% |
| 2026-10-06 | Barclays | $150.00 | ▼ 24% | +6% |
| 2026-08-06 | Baird | $175.00 | — | +24% |
| 2026-08-06 | Bernstein | $175.00 | ▼ 12% | +24% |
| 2026-08-06 | Leerink Partners | $145.00 | — | +3% |
| 2026-08-06 | RBC Capital | $160.00 | ▼ 35% | +13% |
| 2026-08-06 | Raymond James | $180.00 | ▼ 17% | +28% |
| 2026-08-06 | Canaccord Genuity | $179.00 | ▼ 28% | +27% |
| 2026-08-05 | Wells Fargo | $144.00 | — | +2% |
| 2026-08-05 | Truist | $153.00 | ▼ 27% | +8% |
| 2026-07-28 | UBS | $174.00 | ▼ 21% | +23% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $1.7B | +61% | $2.94 | +4100% | est. $1.6B+3% | est. $1.99 | 14 |
| 2024reported | $2.1B | +22% | $5.78 | +97% | est. $2.1B+1% | est. $3.21 | 15 |
| 2025reported | $2.7B | +31% | $3.48 | -40% | est. $2.7B+1% | est. $4.88 | 17 |
| 2026 | $3.3B | +22% | $6.50 | +33% | $3.2B–$3.3B | $6.44–$6.54 | 19 |
| 2027 | $3.7B | +14% | $7.70 | +18% | $3.5B–$3.9B | $7.52–$8.00 | 19 |
| 2028 | $4.3B | +14% | $9.32 | +21% | $3.8B–$4.6B | $8.78–$9.81 | 19 |
| 2029 | $4.9B | +14% | $11.01 | +18% | $4.6B–$5.0B | $10.13–$11.39 | 9 |
| 2030 | $5.1B | +5% | $12.30 | +12% | $4.8B–$5.3B | $11.32–$12.73 | 15 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.